Published in J Cell Biol on July 12, 2004
mTOR signaling in growth control and disease. Cell (2012) 29.21
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell (2010) 10.96
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol (2008) 8.92
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell (2010) 7.59
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A (2005) 7.21
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J (2008) 6.32
Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol (2008) 5.61
Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes (2006) 4.95
Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 4.91
Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev (2006) 4.78
Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol (2004) 4.70
Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol (2009) 4.66
The Lin28/let-7 axis regulates glucose metabolism. Cell (2011) 4.65
Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev (2005) 4.41
A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans (2009) 4.37
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab (2010) 4.08
Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov (2011) 4.05
Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell (2008) 3.91
Class I PI3K in oncogenic cellular transformation. Oncogene (2008) 3.90
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat (2007) 3.78
Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol (2006) 3.67
Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci (2008) 3.64
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol (2008) 3.50
Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci U S A (2007) 3.32
Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol (2009) 3.32
S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell (2006) 3.25
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev (2005) 3.25
mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol (2009) 3.22
Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol (2005) 3.14
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest (2011) 3.00
Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell Metab (2008) 2.96
TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res (2009) 2.96
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) (2009) 2.94
Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol (2009) 2.94
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest (2011) 2.90
Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest (2007) 2.86
The TOR pathway comes of age. Biochim Biophys Acta (2009) 2.83
The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem (2007) 2.77
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 2.71
A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. Biochem J (2007) 2.69
Common corruption of the mTOR signaling network in human tumors. Oncogene (2008) 2.60
mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol (2009) 2.57
Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev (2005) 2.56
Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One (2009) 2.54
mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A (2008) 2.50
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J (2010) 2.43
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res (2009) 2.32
Plzf regulates germline progenitor self-renewal by opposing mTORC1. Cell (2010) 2.29
mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol Metab (2011) 2.28
Regulatory circuits controlling white versus brown adipocyte differentiation. Biochem J (2006) 2.23
Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One (2009) 2.20
FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Dev Cell (2010) 2.11
Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet Muscle (2011) 2.10
TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proc Natl Acad Sci U S A (2006) 2.06
Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia (2012) 2.05
Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev (2005) 1.99
Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol (2007) 1.99
Targeting Mnks for cancer therapy. Oncotarget (2012) 1.96
Progeria syndromes and ageing: what is the connection? Nat Rev Mol Cell Biol (2010) 1.93
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov (2013) 1.93
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2. J Biol Chem (2008) 1.85
Human cytomegalovirus protein UL38 inhibits host cell stress responses by antagonizing the tuberous sclerosis protein complex. Cell Host Microbe (2008) 1.85
mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell (2010) 1.82
Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol Cell Biol (2006) 1.82
Rheb is essential for murine development. Mol Cell Biol (2011) 1.76
p85α SH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation. Mol Cell (2012) 1.76
p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res (2010) 1.74
The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol Cell (2008) 1.73
Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol (2013) 1.73
mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer (2006) 1.72
Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res (2010) 1.70
Irs1 serine 307 promotes insulin sensitivity in mice. Cell Metab (2010) 1.67
Nutrient sensing, metabolism, and cell growth control. Mol Cell (2013) 1.67
mTOR: a pharmacologic target for autophagy regulation. J Clin Invest (2015) 1.61
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev (2012) 1.60
Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord (2008) 1.60
mTOR's role in ageing: protein synthesis or autophagy? Aging (Albany NY) (2009) 1.59
Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res (2008) 1.59
Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res (2009) 1.58
The TSC-mTOR pathway regulates macrophage polarization. Nat Commun (2013) 1.57
Leucine deprivation increases hepatic insulin sensitivity via GCN2/mTOR/S6K1 and AMPK pathways. Diabetes (2011) 1.55
Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol (2004) 1.55
Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res (2011) 1.51
Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res (2007) 1.50
Attenuated mTOR signaling and enhanced autophagy in adipocytes from obese patients with type 2 diabetes. Mol Med (2010) 1.48
Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol (2006) 1.47
Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Mol Cell Biol (2008) 1.46
Emerging role of autophagy in kidney function, diseases and aging. Autophagy (2012) 1.43
Specific killing of Rb mutant cancer cells by inactivating TSC2. Cancer Cell (2010) 1.42
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
The phosphoinositide 3-kinase pathway. Science (2002) 24.72
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol (2002) 17.41
Insulin signalling and the regulation of glucose and lipid metabolism. Nature (2001) 16.41
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol (2002) 8.04
Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell (1993) 7.59
A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet (2002) 7.12
Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature (1995) 7.05
Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell (2003) 6.76
Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol (2003) 6.32
PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci (2001) 6.11
Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science (1997) 6.10
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest (2003) 6.04
Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J (1997) 5.57
Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J (1998) 5.34
The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell (2001) 5.14
Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat Cell Biol (2003) 5.01
Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell (2001) 4.98
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A (2002) 4.93
IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab (2002) 4.93
TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev (2001) 4.68
Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell (2002) 4.35
A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol (2000) 4.25
Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol (2003) 4.20
Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res (1999) 4.04
Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J (1998) 3.94
The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J (1996) 3.78
Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol (2002) 3.68
TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci (2004) 3.56
Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet (1997) 3.56
Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet (1998) 3.54
New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell (2001) 3.52
p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci U S A (2001) 3.11
Essential role of PDK1 in regulating cell size and development in mice. EMBO J (2002) 2.93
Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev (1999) 2.87
Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes Dev (2002) 2.87
Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res (2002) 2.81
The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet (1986) 2.78
gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell (1999) 2.71
New colorimetric method for the quantitative estimation of phospholipids without acid digestion. J Lipid Res (1973) 2.66
Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol (2002) 2.46
Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. Anal Biochem (2003) 2.15
Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol (2001) 2.15
Molecular cloning and characterization of a novel p70 S6 kinase, p70 S6 kinase beta containing a proline-rich region. J Biol Chem (1998) 1.74
Phosphatidylinositol 3-kinase links the interleukin-2 receptor to protein kinase B and p70 S6 kinase. J Biol Chem (1997) 1.69
Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway. J Biol Chem (2000) 1.68
Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression. Cell (1994) 1.67
A single gene encodes two isoforms of the p70 S6 kinase: activation upon mitogenic stimulation. Proc Natl Acad Sci U S A (1992) 1.58
Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am J Pathol (2003) 1.57
Distinct signalling pathways mediate insulin and phorbol ester-stimulated eukaryotic initiation factor 4F assembly and protein synthesis in HEK 293 cells. J Biol Chem (2000) 1.54
Nutrient-dependent and insulin-stimulated phosphorylation of insulin receptor substrate-1 on serine 302 correlates with increased insulin signaling. J Biol Chem (2003) 1.47
Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin. J Biol Chem (2002) 1.29
IGF-I stimulates chemotaxis of human neuroblasts. Involvement of type 1 IGF receptor, IGF binding proteins, phosphatidylinositol-3 kinase pathway and plasmin system. J Endocrinol (2000) 0.98
Insulin-like growth factor-1 (IGF-1), insulin, and epidermal growth factor (EGF) are survival factors for density-inhibited, quiescent Balb/c-3T3 murine fibroblasts. J Cell Physiol (1990) 0.97
Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 12.22
Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol (2008) 4.69
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J (2009) 4.12
PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med (2005) 3.96
Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci (2005) 3.77
Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J (2003) 3.58
Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest (2011) 3.23
PTEN function: how normal cells control it and tumour cells lose it. Biochem J (2004) 3.06
A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. Biochem J (2007) 2.69
A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med (2002) 2.68
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest (2008) 2.68
An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. Nat Biotechnol (2003) 2.53
Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail (2003) 2.45
PTEN: The down side of PI 3-kinase signalling. Cell Signal (2002) 2.34
dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nat Cell Biol (2002) 2.31
Subcellular localization of phosphatidylinositol 4,5-bisphosphate using the pleckstrin homology domain of phospholipase C delta1. Biochem J (2002) 2.16
2-Aminoadipic acid is a biomarker for diabetes risk. J Clin Invest (2013) 2.15
Rational design of a super core promoter that enhances gene expression. Nat Methods (2006) 2.12
Echocardiographic speckle-tracking based strain imaging for rapid cardiovascular phenotyping in mice. Circ Res (2011) 2.06
Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol (2005) 2.00
Metabolic signatures of exercise in human plasma. Sci Transl Med (2010) 1.99
Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation (2012) 1.95
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res (2006) 1.92
Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. Am J Hum Genet (2012) 1.90
Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem (2004) 1.89
The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem J (2004) 1.87
Probing phosphoinositide functions in signaling and membrane trafficking. Trends Cell Biol (2005) 1.87
Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J (2007) 1.74
Biomarkers of cardiovascular stress and incident chronic kidney disease. Clin Chem (2013) 1.71
PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol (2007) 1.62
Arterial stiffness is associated with regional ventricular systolic and diastolic dysfunction: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 1.61
Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol (2011) 1.61
Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids. Biochem J (2003) 1.59
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J (2011) 1.57
Myocardial tissue tagging with cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2009) 1.56
The role of phosphoinositide 3-kinase C2alpha in insulin signaling. J Biol Chem (2007) 1.56
Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake. J Biol Chem (2008) 1.55
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem (2002) 1.53
PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR. Mol Cell (2010) 1.52
Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab (2011) 1.50
Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res (2004) 1.49
Self-administered vaginal swabs are a feasible alternative to physician-assisted cervical swabs for sexually transmitted infection screening in the emergency department. Acad Emerg Med (2009) 1.48
Clinical trial of an educational intervention to achieve recommended cholesterol levels in patients with coronary artery disease. Am Heart J (2004) 1.43
A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol (2013) 1.42
Hyperactivation of mammalian target of rapamycin (mTOR) signaling by a gain-of-function mutant of the Rheb GTPase. J Biol Chem (2006) 1.42
Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem (2008) 1.40
G protein-coupled receptor-mediated activation of p110β by Gβγ is required for cellular transformation and invasiveness. Sci Signal (2012) 1.38
Rationale and design of a multicenter echocardiographic study to assess the relationship between cardiac structure and function and heart failure risk in a biracial cohort of community-dwelling elderly persons: the Atherosclerosis Risk in Communities study. Circ Cardiovasc Imaging (2013) 1.37
Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J Cell Sci (2006) 1.36
A novel leptin signalling pathway via PTEN inhibition in hypothalamic cell lines and pancreatic beta-cells. EMBO J (2006) 1.34
A genome-wide association study of the human metabolome in a community-based cohort. Cell Metab (2013) 1.33
MyosinV controls PTEN function and neuronal cell size. Nat Cell Biol (2009) 1.32
Metabolite profiles during oral glucose challenge. Diabetes (2013) 1.31
Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface. J Biol Chem (2003) 1.31
Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res (2012) 1.30
Cancer-drug discovery and cardiovascular surveillance. N Engl J Med (2013) 1.29
PTEN is destabilized by phosphorylation on Thr366. Biochem J (2007) 1.28
Phosphorylation of histone H3 Thr-45 is linked to apoptosis. J Biol Chem (2009) 1.26
Functional differences between two classes of oncogenic mutation in the PIK3CA gene. Biochem Biophys Res Commun (2009) 1.24
Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J Biol Chem (2002) 1.23
Genetic modifiers of the Drosophila blue cheese gene link defects in lysosomal transport with decreased life span and altered ubiquitinated-protein profiles. Genetics (2007) 1.21
Characterization of a selective inhibitor of inositol hexakisphosphate kinases: use in defining biological roles and metabolic relationships of inositol pyrophosphates. J Biol Chem (2009) 1.17
Hepatocellular carcinoma with intracavitary cardiac involvement: a case report and review of the literature. Am J Cardiol (2008) 1.17
Leptin rapidly improves glucose homeostasis in obese mice by increasing hypothalamic insulin sensitivity. J Neurosci (2010) 1.16
Regulation of insulin receptor substrate 1 pleckstrin homology domain by protein kinase C: role of serine 24 phosphorylation. Mol Endocrinol (2006) 1.16
Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol (2011) 1.15
Differential redox regulation within the PTP superfamily. Cell Signal (2007) 1.15
PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity. Sci Signal (2012) 1.15
Glucose induces an autocrine activation of the Wnt/beta-catenin pathway in macrophage cell lines. Biochem J (2008) 1.14
Development of a long-acting insulin analog using albumin fusion technology. Diabetes (2005) 1.14
Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem (2012) 1.11
Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities. PLoS One (2009) 1.10
Adrenaline potentiates insulin-stimulated PKB activation via cAMP and Epac: implications for cross talk between insulin and adrenaline. Cell Signal (2005) 1.09
Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells. Proc Natl Acad Sci U S A (2013) 1.08
Protein kinase C phosphorylates ribosomal protein S6 kinase betaII and regulates its subcellular localization. Mol Cell Biol (2003) 1.08
Binding of influenza A virus NS1 protein to the inter-SH2 domain of p85 suggests a novel mechanism for phosphoinositide 3-kinase activation. J Biol Chem (2007) 1.08
Evidence that the tandem-pleckstrin-homology-domain-containing protein TAPP1 interacts with Ptd(3,4)P2 and the multi-PDZ-domain-containing protein MUPP1 in vivo. Biochem J (2002) 1.08
Circulating CD34(+) progenitor cell frequency is associated with clinical and genetic factors. Blood (2013) 1.07
Organization of the mouse Ruk locus and expression of isoforms in mouse tissues. Gene (2002) 1.07
Neuregulin signaling on glucose transport in muscle cells. J Biol Chem (2004) 1.07
Dyssynchrony, contractile function, and response to cardiac resynchronization therapy. Circ Heart Fail (2011) 1.05
Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress. J Biol Chem (2010) 1.05
Regulation of phosphoinositide 3-kinase by its intrinsic serine kinase activity in vivo. Mol Cell Biol (2004) 1.05
MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell (2013) 1.05
Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J Clin Invest (2013) 1.04